Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report.
OBJECTIVE
Platinum-based therapy is the cornerstone of ovarian cancer treatment. Development of platinum hypersensitivity can limit therapeutic options. In this brief report, we present case of successful cisplatin administration following two unsuccessful carboplatin desensitization attempts, and without the need for pre-treatment steroids.


METHODS
Retrospective chart review was performed.


RESULTS
One case of recurrent primary peritoneal carcinoma previously treated with a carboplatin-based regimen, developed a platinum hypersensitivity. Two attempts at carboplatin desensitization were unsuccessful. Cisplatin was substituted and the patient achieved a complete response to therapy without further hypersensitivity.


CONCLUSIONS
Platinum-based therapies are vital to the treatment of primary peritoneal and ovarian carcinoma. Protocols that successfully incorporate platinum agents, despite a platinum hypersensitivity, are clinically relevant.
University of Virginia School of Medicine, Charlottesville, VA, USA.
Daniel P
DP
Greene
James Stuart
JS
Ferriss
Amir A
AA
Jazaeri
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D016190:Carboplatin / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D004342:Drug Hypersensitivity / Q000628:therapy*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D017211:Treatment Failure
D000970:Antineoplastic Agents; D016190:Carboplatin; D002945:Cisplatin